Clinical and basic research is a critical component within the Leukemia Section at Moffitt, where patients are offered the opportunity to participate in both early-phase and later-phase clinical trials to test cutting-edge treatments.
Physician researchers within our section lead national and international trials of new treatments, and have presented their results in prominent medical journals and large international meetings. Many of our physicians and scientists collaborate on peer-reviewed, federally funded grant research projects. Members of our section participate in and lead national trials in NCI-funded clinical research programs, including the Southeast Phase 2 Consortium (SEP2C) and the Southwest Oncology Group (SWOG).
Focused areas of research expertise within the Leukemia Section include:
- Immunologic profiling and therapy for MDS
- Chemotherapy strategies to overcome resistance in AML
- Immunologic therapy (vaccines, monoclonal antibodies) in acute and chronic leukemias
- Outcomes research in AML and MDS
- Small molecule and signal transduction inhibitors in acute leukemias and MDS in leukemias
- Cell-adhesion mediated drug resistance (CAM-DR)